CN102688335A - 用于治疗风热感冒的中药组合物及其制备方法 - Google Patents
用于治疗风热感冒的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN102688335A CN102688335A CN201210210629XA CN201210210629A CN102688335A CN 102688335 A CN102688335 A CN 102688335A CN 201210210629X A CN201210210629X A CN 201210210629XA CN 201210210629 A CN201210210629 A CN 201210210629A CN 102688335 A CN102688335 A CN 102688335A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- radix
- preferred
- herba houttuyniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 302
- 239000000203 mixture Substances 0.000 title claims abstract description 194
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 201000009240 nasopharyngitis Diseases 0.000 title abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 239000000284 extract Substances 0.000 claims description 41
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 28
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000003463 adsorbent Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 7
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 7
- 229960003321 baicalin Drugs 0.000 claims description 7
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940126701 oral medication Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 28
- 235000013717 Houttuynia Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 107
- 229940079593 drug Drugs 0.000 description 105
- 239000007788 liquid Substances 0.000 description 69
- 239000000843 powder Substances 0.000 description 37
- 238000002474 experimental method Methods 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 230000036760 body temperature Effects 0.000 description 27
- 206010022000 influenza Diseases 0.000 description 26
- 230000037396 body weight Effects 0.000 description 25
- 238000010790 dilution Methods 0.000 description 25
- 239000012895 dilution Substances 0.000 description 25
- 241000894006 Bacteria Species 0.000 description 24
- 239000008354 sodium chloride injection Substances 0.000 description 23
- 241000700605 Viruses Species 0.000 description 19
- 241000700159 Rattus Species 0.000 description 16
- 241000191967 Staphylococcus aureus Species 0.000 description 14
- 230000000844 anti-bacterial effect Effects 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 241000701161 unidentified adenovirus Species 0.000 description 14
- 239000012153 distilled water Substances 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 241000712461 unidentified influenza virus Species 0.000 description 13
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 230000001681 protective effect Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 230000003203 everyday effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000003501 vero cell Anatomy 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 231100000668 minimum lethal dose Toxicity 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000000436 anus Anatomy 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 231100001274 therapeutic index Toxicity 0.000 description 9
- 206010037660 Pyrexia Diseases 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000008187 granular material Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 241000712431 Influenza A virus Species 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 208000000114 Pain Threshold Diseases 0.000 description 6
- 241000194017 Streptococcus Species 0.000 description 6
- 241000193998 Streptococcus pneumoniae Species 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 239000002662 enteric coated tablet Substances 0.000 description 6
- 230000002949 hemolytic effect Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 6
- 108010006464 Hemolysin Proteins Proteins 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000012930 cell culture fluid Substances 0.000 description 5
- 239000003228 hemolysin Substances 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 231100000645 Reed–Muench method Toxicity 0.000 description 4
- 208000037386 Typhoid Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- -1 suspensoid Substances 0.000 description 4
- 201000008297 typhoid fever Diseases 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000031636 Body Temperature Changes Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000002155 anti-virotic effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 230000000384 rearing effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 239000003532 endogenous pyrogen Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229960002800 prednisolone acetate Drugs 0.000 description 2
- 238000011085 pressure filtration Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- LTGPFZWZZNUIIK-LURJTMIESA-N Lysol Chemical compound NCCCC[C@H](N)CO LTGPFZWZZNUIIK-LURJTMIESA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003814 hair luster Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108010052620 leukocyte endogenous mediator Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- JWHHANVGNNWIRI-UHFFFAOYSA-N methanol phosphoric acid hydrate Chemical compound O.OC.OP(O)(O)=O JWHHANVGNNWIRI-UHFFFAOYSA-N 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010010998 polyactin A Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 229940041022 streptomycins Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210210629.XA CN102688335B (zh) | 2012-06-25 | 2012-06-25 | 用于治疗风热感冒的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210210629.XA CN102688335B (zh) | 2012-06-25 | 2012-06-25 | 用于治疗风热感冒的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102688335A true CN102688335A (zh) | 2012-09-26 |
CN102688335B CN102688335B (zh) | 2014-01-01 |
Family
ID=46854179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210210629.XA Active CN102688335B (zh) | 2012-06-25 | 2012-06-25 | 用于治疗风热感冒的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102688335B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106924448A (zh) * | 2017-01-10 | 2017-07-07 | 湖南华纳大药厂天然药物有限公司 | 治疗风热感冒的药物组合物及其制备方法 |
CN111249318A (zh) * | 2020-03-11 | 2020-06-09 | 湖南新汇制药股份有限公司 | 一种治疗风热感冒的猴头菌培养基、桑叶猴头菌转化菌丝体、提取物和应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07118160A (ja) * | 1993-10-22 | 1995-05-09 | Daiichi Yakuhin Kogyo Kk | 抗ウイルス剤 |
AU2004201961A1 (en) * | 2003-12-30 | 2005-07-14 | National Defense Medical Center | Pharmaceutical composition and medicine for external use containing antiviral component from houttuynia cordata |
KR20060040418A (ko) * | 2004-11-05 | 2006-05-10 | 주식회사 엘지생활건강 | 항 인플루엔자 바이러스 효과를 갖는 천연 추출물 및 그조성물 |
CN1957999A (zh) * | 2005-10-31 | 2007-05-09 | 成都华神集团股份有限公司 | 一种中药组合物及其制备方法和质量控制方法 |
WO2009088042A1 (ja) * | 2008-01-10 | 2009-07-16 | Jcs Inc. | インフルエンザウイルス感染を予防するための散布剤 |
CN101850013A (zh) * | 2010-05-26 | 2010-10-06 | 广州中医药大学热带医学研究所 | 一种治疗感冒的中药滴鼻剂及其制剂质控方法和应用 |
CN102188533A (zh) * | 2010-03-03 | 2011-09-21 | 鲁南厚普制药有限公司 | 一种治疗风热感冒的口服液体制剂及其制备方法 |
JP2012044982A (ja) * | 2010-08-26 | 2012-03-08 | Miyazaki Mokuzaiten:Kk | 健康茶 |
-
2012
- 2012-06-25 CN CN201210210629.XA patent/CN102688335B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07118160A (ja) * | 1993-10-22 | 1995-05-09 | Daiichi Yakuhin Kogyo Kk | 抗ウイルス剤 |
AU2004201961A1 (en) * | 2003-12-30 | 2005-07-14 | National Defense Medical Center | Pharmaceutical composition and medicine for external use containing antiviral component from houttuynia cordata |
KR20060040418A (ko) * | 2004-11-05 | 2006-05-10 | 주식회사 엘지생활건강 | 항 인플루엔자 바이러스 효과를 갖는 천연 추출물 및 그조성물 |
CN1957999A (zh) * | 2005-10-31 | 2007-05-09 | 成都华神集团股份有限公司 | 一种中药组合物及其制备方法和质量控制方法 |
WO2009088042A1 (ja) * | 2008-01-10 | 2009-07-16 | Jcs Inc. | インフルエンザウイルス感染を予防するための散布剤 |
CN102188533A (zh) * | 2010-03-03 | 2011-09-21 | 鲁南厚普制药有限公司 | 一种治疗风热感冒的口服液体制剂及其制备方法 |
CN101850013A (zh) * | 2010-05-26 | 2010-10-06 | 广州中医药大学热带医学研究所 | 一种治疗感冒的中药滴鼻剂及其制剂质控方法和应用 |
JP2012044982A (ja) * | 2010-08-26 | 2012-03-08 | Miyazaki Mokuzaiten:Kk | 健康茶 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106924448A (zh) * | 2017-01-10 | 2017-07-07 | 湖南华纳大药厂天然药物有限公司 | 治疗风热感冒的药物组合物及其制备方法 |
CN106924448B (zh) * | 2017-01-10 | 2020-04-24 | 湖南华纳大药厂天然药物有限公司 | 治疗风热感冒的药物组合物及其制备方法 |
CN111249318A (zh) * | 2020-03-11 | 2020-06-09 | 湖南新汇制药股份有限公司 | 一种治疗风热感冒的猴头菌培养基、桑叶猴头菌转化菌丝体、提取物和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102688335B (zh) | 2014-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102114044B (zh) | 一种人工加工熊胆粉及其制备方法 | |
CN102068492B (zh) | 抗病毒中草药组合物、中药组合物及其制备方法 | |
CN100486635C (zh) | 一种治疗咽炎的中药 | |
CN1883560B (zh) | 一种含金莲花的中药复方制剂及其制备方法 | |
CN102688332B (zh) | 一种治疗感冒的中药组合物及其制备方法 | |
CN114053343A (zh) | 一种中药组合物、制备方法及应用 | |
CN101628108B (zh) | 治疗外感风寒的中药颗粒剂及其制备方法 | |
CN103130865A (zh) | 苦参碱、氧化苦参碱甘草次酸复盐及其制备方法、用途 | |
CN102318746B (zh) | 一种用于细菌性畜禽疾病的动物保健品 | |
CN102688335B (zh) | 用于治疗风热感冒的中药组合物及其制备方法 | |
CN1939414B (zh) | 一种具有抗菌消炎作用的药物组合物 | |
CN102068464B (zh) | 六神曲抗菌、抗病毒有效部位提取物及其医药用途 | |
CN103285230A (zh) | 用于治疗咽炎的药物组合物及其制备方法 | |
CN1947749B (zh) | 一种由头花蓼和茯苓制成的药物组合物 | |
CN104474021A (zh) | 治疗表热的中药组合物及其制备方法 | |
CN100531757C (zh) | 一种治疗风热型感冒的药物组合物及其制备方法 | |
CN1939412B (zh) | 一种由北豆根与新鱼腥草素钠制成的药物组合物 | |
CN101073625B (zh) | 一种具有抗感染和抗炎作用的药物组合物 | |
CN104825852B (zh) | 一种藏药组合物及其制备方法和应用 | |
CN103211878B (zh) | 一种抗感染的中药组合物及其制备方法 | |
CN107982356A (zh) | 一种治疗呼吸道感染的口服药物 | |
CN107875215B (zh) | 一种用于贫血的中药组合物 | |
CN102697800B (zh) | 繁缕多糖组合物及其在制备抗病毒药物中的应用 | |
CN1939380B (zh) | 一种抗感染、抗病毒以及解热镇痛的药物组合物 | |
CN109470788A (zh) | 一种妇科千金片的质量控制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine composition for treating wind-heat type common cold and preparation method of Chinese medicine composition Effective date of registration: 20190624 Granted publication date: 20140101 Pledgee: Industrial Bank Limited by Share Ltd Xi'an branch Pledgor: Xi'an Xintong Pharmaceutical Research Co., Ltd. Registration number: 2019610000130 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200824 Granted publication date: 20140101 Pledgee: Industrial Bank Limited by Share Ltd. Xi'an branch Pledgor: XI'AN XINTONG PHARMACY RESEARCH Co.,Ltd. Registration number: 2019610000130 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Traditional Chinese medicine composition for treating wind heat and cold and its preparation method Effective date of registration: 20200826 Granted publication date: 20140101 Pledgee: Industrial Bank Limited by Share Ltd. Xi'an branch Pledgor: XI'AN XINTONG PHARMACY RESEARCH Co.,Ltd. Registration number: Y2020610000132 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 710077 No. 69 Jinye Road, Xi'an High-tech Zone, Shaanxi Province Patentee after: Xi'an Xintong Pharmaceutical Research Co.,Ltd. Address before: 710077 No. 69 Jinye Road, Xi'an High-tech Zone, Shaanxi Province Patentee before: XI'AN XINTONG PHARMACY RESEARCH Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220214 Granted publication date: 20140101 Pledgee: Industrial Bank Limited by Share Ltd. Xi'an branch Pledgor: XI'AN XINTONG PHARMACEUTICAL RESEARCH Co.,Ltd. Registration number: Y2020610000132 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |